☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Uveal Melanoma40–50 pages · PDF + Excel tracker

Uveal Melanoma Drug Pipeline: 33 Assets by Phase

Uveal Melanoma pipeline: 33 drug candidates in clinical development, 5 in Phase III, from 22 sponsors. Data as of 4 Oct 2026.

Pipeline Terminal Uveal Melanoma Data as of 4 Oct 2026
Candidates in development 33assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 515% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 927% of pipeline Registry
Phase I 1958% of pipeline Registry
Sponsors 22top 5 hold 42% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 14464 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 4 Oct 2021.
Readouts in 12 months 7Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 10170% · Europe 33% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I19
Phase II9
Phase III5

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
TebentafuspPhase IIDec 2026 (est.)
DacarbazinePhase II/IIIJan 2027 (est.)
CrizotinibPhase II/IIIJan 2027 (est.)

Candidates in development by lead sponsor

iOnctura4
IDEAYA Biosciences4
OncoNano Medicine, Inc.2
Immatics US, Inc.2
Xencor, Inc.2

Phase II and III primary completions per quarter

Q4 20261
Q1 20276
Q2 20270
Q3 20270
Q4 20273
Q1 20280
Q2 20280
Q3 20280

Answers at a glance

  • 5 of 33 uveal melanoma candidates (15%) are in Phase III.
  • iOnctura runs the largest uveal melanoma pipeline, with 4 candidates.
  • 7 readouts are due in 12 months; the next is Tebentafusp in Dec 2026.
  • 32 trials are recruiting patients now; 70% of all trials have a US site and 33% a European one.
33 candidates144 trials28 countriesData as of 4 Oct 2026Next refresh by 2 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 4 Oct 2026 Next refresh: by 2 Jan 2027 Change: First edition

Request a free sample

A sample of the Uveal Melanoma Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Uveal Melanoma has 33 drug candidates in active clinical development, of which 5 are in Phase III, 9 in Phase II and 19 in Phase I, according to Douglas Insights' count of 144 interventional trials registered on ClinicalTrials.gov (data as of 4 Oct 2026).

The uveal melanoma drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many uveal melanoma drugs are in each phase of development?

Douglas Insights counts 5 uveal melanoma candidates in Phase III, 15% of the 33 assets in development; Phase II holds 9 and Phase I holds 19.

Phase I19Phase II9Phase III5
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 4 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III515%
Phase II927%
Phase I1958%
Total33100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each uveal melanoma asset appears in exactly one row. The 64 trials still recruiting or running carry 44% of the 144 registered trials in scope.

How many uveal melanoma trials are recruiting patients now?

32 uveal melanoma trials are recruiting patients and 5 more have not started recruiting yet, out of 144 interventional trials in scope; together they make up 26% of the trial base.

Registry statusTrialsShare
Completed5740%
Recruiting3222%
Active, not recruiting2618%
Terminated1712%
Not yet recruiting53.5%
Status not verified42.8%
Withdrawn21.4%
Enrolling by invitation10.7%

Terminated, suspended and withdrawn uveal melanoma trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the uveal melanoma pipeline?

iOnctura leads the uveal melanoma pipeline with 4 candidates; the top 5 sponsors hold 42% of the 33 assets, and 22 sponsors run at least one.

SponsorAssets in developmentShare
iOnctura412%
IDEAYA Biosciences412%
OncoNano Medicine, Inc.26.1%
Immatics US, Inc.26.1%
Xencor, Inc.26.1%

Industry sponsors lead 52 of the 144 uveal melanoma trials (36%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the uveal melanoma pipeline?

Mechanism and drug-type classification for the 33 uveal melanoma candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What uveal melanoma trial readouts are coming next?

7 uveal melanoma candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
TebentafuspImmunocore LtdPhase IIDec 2026 (estimated)NCT05315258
DacarbazineIDEAYA BiosciencesPhase II/IIIJan 2027 (estimated)NCT05987332
CrizotinibIDEAYA BiosciencesPhase II/IIIJan 2027 (estimated)NCT05987332

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many uveal melanoma readouts fall in each quarter?

10 uveal melanoma candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 6, due in Q1 2027.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026011
Q1 2027066
Q2 2027000
Q3 2027000
Q4 2027123
Q1 2028000
Q2 2028000
Q3 2028000

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most uveal melanoma trials?

United States hosts the most uveal melanoma trials, with sites in 101 of the 144 studies (70%); trials in scope run in 28 countries in all.

CountryTrials with a siteShare of trials
United States10170%
France2316%
Spain1913%
Australia1813%
Germany1611%
United Kingdom149.7%
Canada139.0%
Netherlands128.3%

A multinational uveal melanoma trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are uveal melanoma drugs being tested?

101 of the 144 uveal melanoma trials (70%) have a site in the United States, 48 (33%) in Europe and 1 (0.7%) in China; 24 of the 33 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States10170%24FDA
Europe (EU/EEA, UK, Switzerland)4833%19EMA, MHRA, Swissmedic
China10.7%1NMPA
Japan10.7%0PMDA
Rest of world2417%16national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational uveal melanoma trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the uveal melanoma pipeline since the last update?

This is the first edition of the uveal melanoma pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the uveal melanoma pipeline?

Douglas Insights read 144 interventional trials registered on ClinicalTrials.gov for the conditions "Uveal Melanoma", "ocular melanoma" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 33 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Uveal Melanoma Pipeline Review include?

The Uveal Melanoma Pipeline Review covers all 33 candidates in an Excel tracker and profiles the leading 25 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 33 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where uveal melanoma treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every uveal melanoma candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in uveal melanoma, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Uveal Melanoma review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the uveal melanoma pipeline

How many drugs are in the uveal melanoma pipeline?

33 drug candidates are in active clinical development for uveal melanoma, with 5 in Phase III, per Douglas Insights (data as of 4 Oct 2026).

Which company has the most uveal melanoma drugs in development?

4 candidates make iOnctura the largest uveal melanoma pipeline sponsor, out of 22 sponsors counted by Douglas Insights.

When is the next uveal melanoma trial readout?

Dec 2026 is the registered primary completion of the Phase II trial of Tebentafusp (NCT05315258), the next uveal melanoma catalyst in Douglas Insights' calendar.

How many uveal melanoma trials run in the United States and Europe?

101 uveal melanoma trials have a US site and 48 a European site, out of 144 registered trials counted by Douglas Insights (data as of 4 Oct 2026).

How often is the uveal melanoma pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 4 Oct 2026 and the next is due by 2 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Uveal Melanoma Drug Pipeline, data as of 4 Oct 2026. https://www.douglasinsights.com/pipeline/uveal-melanoma/